← All Posts
Emergent BioSolutions Inc.
April 30, 2026
•
Author: Phil Ratcliff
| Item |
Proposal |
Vote |
| 1 |
To elect four Class II directors to hold office for a term expiring at our 2029 Annual Meeting of Stockholders, each to serve until their respective successors are duly elected and qualified |
|
| 1a |
Sujata Dayal |
✓ For(638.236)
|
| 1b |
John Fowler, Jr. |
✓ For(638.236)
|
| 1c |
Zsolt Harsanyi, Ph.D. |
✓ For(638.236)
|
| 1d |
Joseph Papa |
✗ Against(638.236)
|
| 2 |
To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. |
✓ For(638.236)
|
| 3 |
To hold, on an advisory basis, a vote to approve the 2025 compensation of our named executive officers. |
✓ For(638.236)
|
| 4 |
To approve an amendment to the Emergent BioSolutions Inc. Amended and Restated Stock Incentive Plan to increase the number of shares of common stock for the grant of awards under the plan. |
✓ For(638.236)
|
| 5 |
The transaction of such other business as may properly come before the meeting. |
Informational(638.236)
|
This article was written for information purposes only and its content should not be
construed by any consumer and/or prospective client as rebel Financial's solicitation
to affect, or attempt to affect transactions in securities, or the rendering of
personalized investment advice for compensation. No client or prospective client should
assume that any such discussion serves as the receipt of, or a substitute for,
personalized advice from rebel Financial, or from any other investment professional.
See our disclosures page for more information.
rebel Financial